Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02581072 · ClinicalTrials.gov registry record · Phase 1
A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204
A Phase 1 study of Acne Vulgaris, sponsored by Novan.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT02581072 is a Phase 1 study of Acne Vulgaris that has completed, run by Novan. The registered enrollment target is 56 participants, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02581072, a Phase 1 study of Acne Vulgaris, has completed, sponsored by Novan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
A Double-Blind, Double-Dummy, Randomized, 4-Period Crossover Study to Define the ECG Effects of SB204 Using a Clinical and Supratherapeutic Dose Compared with Placebo and Moxifloxacin (a Positive Control) in Subjects with Acne Vulgaris: A Thorough ECG Study
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG SB204 4%
- DRUG SB204 8% or 12%
Study Locations (1)
Wisconsin
- Spaulding Clinical Research, LLC - West Bend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02581072
The ClinicalTrials.gov registry entry for NCT02581072 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (80% lower). The listed sponsor is Novan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 3 interventions - of which Vehicle is the first listed.
NCT02581072 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT02581072 about?
NCT02581072 is a clinical study titled "A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204". A Double-Blind, Double-Dummy, Randomized, 4-Period Crossover Study to Define the ECG Effects of SB204 Using a Clinical and Supratherapeutic Dose Compared with Placebo and Moxifloxacin (a Positive Control) in Subjects with Acne Vulgaris: A Thorough ECG Study
What is the current status of trial NCT02581072?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2015-10. Estimated completion is 2016-04.
What conditions does trial NCT02581072 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT02581072?
The interventions under investigation include: Vehicle (DRUG), SB204 4% (DRUG), SB204 8% or 12% (DRUG).
Who is sponsoring clinical trial NCT02581072?
This trial is sponsored by Novan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02581072 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy
RECRUITING · Phase 1
-
Lipidome and Microbiome Profile of Acne
ACTIVE NOT RECRUITING · Phase 1
-
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris
COMPLETED · Phase 1
-
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
COMPLETED · Phase 1
-
A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers
COMPLETED · Phase 1
-
A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.